This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Charles River (CRL) to Advance AI Drug Discovery With New Pact
by Zacks Equity Research
Charles River's (CRL) recent partnership will enable the optimization of the discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.
Charles River's (CRL) Q3 Earnings Beat, Margins Decline
by Zacks Equity Research
Charles River's (CRL) RMS organic revenue growth is primarily driven by research model services, particularly the Insourcing Solutions business.
Charles River (CRL) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Unlocking Q3 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Charles River (CRL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.
Earnings Preview: Charles River Laboratories (CRL) Q3 Earnings Expected to Decline
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River (CRL) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Charles River's (CRL) CRADLE initiative and research models in North America and China are anticipated to have maintained their growth momentum in the third quarter.
Why Charles River (CRL) Could Beat Earnings Estimates Again
by Zacks Equity Research
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charles River (CRL) Offers Access to Preclinical Cancer Research
by Zacks Equity Research
Charles River (CRL) contributes to 84 percent of the FDA-approved cancer medicines and provides partners with 16 oncology prospects.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on robust RMS segment growth and upbeat guidance.
Charles River (CRL) Launches LVV-based Gene Therapy Platform
by Zacks Equity Research
Charles River's (CRL) LVV platform provides medicinal developers with an efficient, dependable route to the clinic and the market.
Charles River (CRL) Opens a RightSource Lab in Stevenage
by Zacks Equity Research
Charles River's (CRL) new RightSource facility is likely to provide services to the Stevenage advanced therapy biocluster.
Charles River (CRL) Announces Partnership With Related Sciences
by Zacks Equity Research
Charles River's (CRL) new collaboration is likely to leverage the AI-powered drug discovery and development platform, Logica.
Charles River (CRL) Down 6.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on the RMS segment's continued growth and upbeat guidance.
Charles River (CRL) Gains From Global Demand Amid FX Woes
by Zacks Equity Research
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) Collaborates With Fondazione Telethon
by Zacks Equity Research
Charles River (CRL) is excited about Fondazione Telethon's collaboration to produce HQ plasmid DNA for the lentivirus used in ex vivo gene therapy developed by Fondazione Telethon.
Charles River (CRL) Q2 Earnings Top, 2023 View Narrowed
by Zacks Equity Research
Charles River (CRL) registers robust growth in small research models, research model services and the Safety Assessment business.
Here's What Key Metrics Tell Us About Charles River (CRL) Q2 Earnings
by Zacks Equity Research
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Charles River Laboratories (CRL) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 2.28% and 1.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of 11.01% and 8.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Charles River (CRL) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Continued global demand for research models and associated services' strong DSA segment performance is likely to have driven Charles River's (CRL) Q2 revenues.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on strategic acquisitions and robust performance of the DSA and RMS arms.
Charles River's (CRL) Improved Volume Aids Amid Margin Woe
by Zacks Equity Research
Charles River (CRL) registers growth in small research models, research model services and the Cell Solutions business.
Charles River (CRL) Introduces LVV Packaging Plasmids
by Zacks Equity Research
Charles River (CRL) launches packaging plasmids to accelerate and standardize lentiviral vector development.
Charles River (CRL) Inks a CDMO Partnership for Bladder Cancer
by Zacks Equity Research
Curigin's oncolytic RNAi gene therapies are set to leverage Charles River's (CRL) expertise in CDMO solutions.